Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by<i>Staphylococcus aureus</i>

Fowler, Vance G.; Boucher, Helen W.; Corey, G. Ralph; Abrutyn, Elías; Karchmer, Adolf W.; Rupp, Mark E.; Levine, Donald P.; Chambers, Henry F.; Tally, Francis P.; Vigliani, Gloria; Cabell, Christopher H.; Link, Arthur S.; Demeyer, Ignace; Filler, Scott G.; Zervos, Marcus J.; Cook, Paul P.; Parsonnet, Jeffrey; Bernstein, Jack; Price, Connie S.; Forrest, Graeme N.; Fätkenheuer, Gerd; Gareca, Marcelo; Rehm, Susan J.; Brodt, H.-R.; Tice, Alan D.; Cosgrove, Sara E.

doi:10.1056/nejmoa053783

Cited by 1,345 publications

(978 citation statements)

References 25 publications

Supporting

Mentioning

891

Contrasting

Unclassified

Order By: Relevance

“…Guidelines for the management of intravascular device-associated bacteremia have been published by the Infectious Diseases Society of America (IDSA) and other organizations, 15,16 and recent studies have demonstrated the effectiveness of newer agents for the management of SAB. 17 Nevertheless, there is still controversy regarding some aspects of the management of SAB (eg, duration of therapy, criteria for echocardiographic evaluation, role of combination therapy). The presence of SABU, the marker evaluated in our study, may be an additional factor to consider when deciding upon duration of therapy and whether to obtain echocardiography or other imaging.…”

Section: Discussionmentioning

confidence: 99%

Staphylococcus aureus bacteremia (SAB) with associated S. aureus bacteriuria (SABU) as a predictor of complications and mortality

Perez-Jorge

Burdette

Markert

et al. 2010

Journal of Hospital Medicine

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVES:Staphylococcus aureus (SA) bacteremia (SAB) is associated with a high rate of complications, most of which are related to hematogenous seeding into deep tissues or prosthetic material. SA bacteriuria (SABU) has been described in association with SAB, but has not been evaluated as a predictor for complicated bacteremia, which was the objective of our study.METHODS (DESIGN, SETTING, AND PATIENTS):We conducted a retrospective study of patients admitted to the hospital with SAB. The 118 patients included in the study were divided in 2 cohorts: a group with SABU and a group without SA in the urine. We followed the 2 cohorts for an average of 8 months and evaluated the differences in complications and mortality.RESULTS:SABU was found in 28 of 118 patients with SAB. Eighteen patients (64%) in this group had complications from the bacteremia, while in the group without SABU only 33% (30/90 patients) had complications (P = 0.004). The SABU group also had more deaths (32% vs. 14%; P = 0.036).CONCLUSIONS:In this population of hospitalized patients with SAB, the presence of SABU was associated with an increased risk of early complications, including septic shock, and with higher mortality. A routine urine culture in search of SABU may be a helpful tool for detection of those patients with SAB who are at increased risk of complications and death. Journal of Hospital Medicine 2010;5:208–211. © 2010 Society of Hospital Medicine.

show abstract

Section: Discussionmentioning

confidence: 99%

Staphylococcus aureus bacteremia (SAB) with associated S. aureus bacteriuria (SABU) as a predictor of complications and mortality

Perez-Jorge

Burdette

Markert

et al. 2010

Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…6 Daptomycin was licensed from Lilly to Cubist Pharmaceuticals 7 , and has been approved for the treatment of difficult-to-treat skin and skin structure infections caused by Gram-positive pathogens, 8 and for bacteremia and right-sided endocarditis caused by Staphylococcus aureus, including strains resistant to methicillin (MRSA (methicillin-resistant S. aureus)). 9 Daptomycin failed to meet noninferiority standards in a clinical trial for community-acquired pneumonia caused by Streptococcus pneumoniae, 10 apparently because it becomes sequestered in lung surfactant. 11 Many derivatives of A21978C have been made by chemical modifications of the lipid side chain or by additions to the d-amino group of ornithine (Orn 6 ), but none have yet proven superior to daptomycin.…”

Section: Introductionmentioning

confidence: 99%

Genomics and the ancient origins of the daptomycin biosynthetic gene cluster

Baltz¹

2010

J Antibiot

View full text Add to dashboard Cite

Daptomycin is a clinically useful lipopeptide antibiotic produced by Streptomyces roseosporus. The antibiotic is assembled by a nonribosomal peptide synthetase (NRPS) mechanism, and the cyclized tridecapeptide contains three non-proteinogenic L-amino acids: ornithine (Orn), 3-methyl-glutamic acid (3mGlu) and kynurinine (Kyn). Daptomycin also has three D-amino acids. The two genes that encode proteins involved in the formation of 3mGlu and Kyn have no known orthologs, and hence they are good probes to search for daptomycin-like gene clusters among newly sequenced actinomycete genomes. A recent search with these genes revealed a daptomycin-like gene cluster in Saccharomonospora viridis, a causative agent for farmer's lung disease. S. viridis has a genome of 4.3 Mb, which is about one half the size of Streptomyces genomes. Searches for other NRPS and polyketide synthase (PKS) genes revealed only one other NRPS gene and no PKS genes in S. viridis. The orthologous lipopeptide biosynthetic genes and gene products in S. viridis and S. roseosporus have diverged extensively from a last common ancestor dating back to a pathway that had evolved over 1 billion years ago.

show abstract

“…The endpoints used in a published randomised controlled trial (RCT) of daptomycin vs. vancomycin for treatment of BSI, which used a primary outcome of clinical success at 42 days (with failure defined by clinical and microbiological factors as well as protocol violations) [21] came under criticism. Concerns included failure defined by starting a non-study antibiotic for a secondary infection, or failing to take protocol blood cultures.…”

Section: Composite Endpointsmentioning

confidence: 99%

Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition

Harris

McNamara

Lye

et al. 2017

Clinical Microbiology and Infection

View full text Add to dashboard Cite

No standardised endpoint definitions exist to aid the design of trials that compare antibiotic therapies for bloodstream infection (BSI). We reviewed endpoints used in contemporary BSI studies and defined consensus endpoints using a modified Delphi process. Prospective studies, randomised trials or registered protocols comparing antibiotic therapies for BSI, published from 2005 to 2016, were reviewed. Different primary and secondary endpoints were defined for pilot (small-scale studies designed to evaluate protocol design, feasibility and implementation) and definitive trials (larger-scale studies designed to test hypotheses and influence clinical practice), as well as for Staphylococcus aureus and Gram-negative BSI. For pilot studies of S.

show abstract

Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused byStaphylococcus aureus

Abstract: Daptomycin (6 mg per kilogram daily) is not inferior to standard therapy for S. aureus bacteremia and right-sided endocarditis. (ClinicalTrials.gov number, NCT00093067 [ClinicalTrials.gov].).

Cited by 1,345 publications

References 25 publications

Staphylococcus aureus bacteremia (SAB) with associated S. aureus bacteriuria (SABU) as a predictor of complications and mortality

Staphylococcus aureus bacteremia (SAB) with associated S. aureus bacteriuria (SABU) as a predictor of complications and mortality

Genomics and the ancient origins of the daptomycin biosynthetic gene cluster

Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition

Contact Info

Product

Resources

About